ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ)
$23.85 0.1 (0.4211%)
Analysed ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) News Sources
Here's Why You Should Add ARQT Stock to Your Portfolio Now
28-08-2026
yahoo.com
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
02-09-2026
yahoo.com
Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
24-08-2026
yahoo.com
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
27-08-2026
yahoo.com
Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates
05-08-2026
yahoo.com
Arcutis Biotherapeutics Q2 Earnings Call Highlights
05-08-2026
marketbeat.com
Arcutis Biotherapeutics Inc (ARQT) (Q2 2026) Earnings Call Highlights: Revenue Surges 59% and ...
06-08-2026
yahoo.com
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability
06-08-2026
fool.com
Arcutis (ARQT) Q2 2026 Earnings Call Transcript
12-08-2026
fool.com
Arcutis Biotherapeutics (ARQT) Faces A Valuation Test, Is It Still A Bargain?
28-08-2026
yahoo.com
What is the current price of ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ)?
The current price of ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) is $23.85.
ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) absolute price change since previous trading day?
The absolute price change of ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) since the previous trading day is $0.1.
ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) percentage price change since previous trading day?
The percentage price change of ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) since the previous trading day is 0.4211%.
What is the most recent average sentiment score for ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ)?
The most recent average sentiment score for ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) is 81 out of 100.
What is the most recent average sentiment for ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ)?
The most recent sentiment for ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) is .
SEC-8K** Filing Available For ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.